Cardiac arrest has a dire prognosis, with an average of only 5% of patients being discharged alive without neurologic problems after an out-of-hospital cardiac arrest (1). Despite improvements in medical therapy and other devices modifying ventilatory support (2, 3) cardiopulmonary support based especially on closed chest compression is pivotal to maximize survival chances. However, manual chest compression is energy consuming and operator-intensive. Moreover, it cannot be performed successfully for a prolonged period of time by any individual healthcare provider nor in logistically challenging settings (e.g. helicopters).
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Manual chest compression appears particularly challenging for patients in cardiac arrest who also require an emergent invasive procedure, such as primary percutaneous coronary intervention (PCI). The LUCAS device (LUCAS 2, Jolife, Lund, Sweden) is a mechanical chest compression-decompression system which enabled automated and continuous closed chest compression, without unduly limiting other invasive procedures such as PCI (4) (5) (6) (7) (8) (9) . It is unclear however whether the LUCAS device can really impact on the patient prognosis besides enabling uninterrupted PCI during a prolonged cardiac arrest, as exemplified by a recent case we have faced.
Use of the LUCAS mechanical chest compression device for percutaneous coronary intervention during cardiac arrest: is it really a game changer? A 40-year-old gentleman with long-standing type 1 diabetes mellitus was admitted to a spoke care center for suspected acute myocardial infarction, based on typical chest pain and diffuse non-ST-elevation myocardial infarction. Shortly after admission to the emergency room, the patient developed cardiac arrest due to ventricular fibrillation: He was successfully defibrillated but then developed pulseless electrical activity (PEA) despite several boluses of adrenaline. After tracheal intubation and mechanical ventilation, and while still under continuous manual chest compression, he was transferred to our hub care center for further management. At arrival in our emergency department, systemic thrombolysis was attempted. Given its lack of efficacy and the persistence of cardiac arrest due to (PEA), the LUCAS device was positioned and activated. The patient was thus transported to the cardiac catheterization laboratory, where selective coronary angiography was performed during continuous mechanical chest compression. A thrombotic subocclusion of the left main coronary stem was demonstrated, together with chronic total occlusions of the distal left anterior descending and distal right coronary artery (Figure 1) . Thus, left main stenting was performed by means of PCI and 3.5x25 mm bare-metal stent implantation (Skylor, Invatec, Roncadelle, Italy) dilated at up to 20 atmospheres, achieving a satisfactory final result in terms of residual stenosis. Despite this, no return of spontaneous circulation was possible, and the resuscitation efforts were interrupted 30 minutes after the end of the procedure. The following day, a post-mortem confirmed the acute myocardial infarction as the cause of death and the chronic occlusion of the distal left anterior descending and distal right coronary artery, as well as showing a good patency of the implanted stent. Despite the promising features of the LU-CAS device, the only available randomized trial on this topic, including 149 patients with out-of-hospital cardiac arrest, appears in agreement with our case study (10) . Indeed, in this study Smekal et al did not show a statistically or clinically significant benefit from the use of the device (6 of those treated with the LUCAS system discharged alive versus 7 of those treated with manual compression, p=0.8) (10) . Similar uncertainty stems from a negative prior study on the Autopulse Resuscitation System (Zoll, Chelmsford, MA, USA) (11) , and an inconclusive recent Cochrane Collaboration systematic review including 4 trials and 868 patients (12) . Whereas a combined use of LUCAS and extra-corporeal membrane oxygenation (ECMO) systems would have been appealing in our case and is under investigation, its purported benefits remain largely speculative and require further scientific proof. Thus, awaiting the results of the upcoming 4000-patient Prehospital Randomised Assessment of a Mechanical compression Device In Cardiac arrest (PaRAMeDIC) trial (13), we believe that the LUCAS device should best be reserved to patients with cardiac arrest without an ominous prognosis per se.
